Last reviewed · How we verify
Matching Placebo to JNJ-77242113
Matching Placebo to JNJ-77242113 is a Small molecule drug developed by Janssen Research & Development, LLC. It is currently in Phase 3 development.
This is a placebo control formulation matching the inactive vehicle and appearance of JNJ-77242113 for blinded clinical trial comparison.
At a glance
| Generic name | Matching Placebo to JNJ-77242113 |
|---|---|
| Sponsor | Janssen Research & Development, LLC |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Matching placebos are used in randomized controlled trials to maintain blinding and reduce bias. This placebo is formulated to be indistinguishable from the active JNJ-77242113 drug product in appearance, taste, and administration route, allowing patients and investigators to remain unaware of treatment assignment during the Phase 3 trial.
Approved indications
Common side effects
Key clinical trials
- A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis (PHASE3)
- A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-naïve Participants With Active Psoriatic Arthritis (PHASE3)
- A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced Participants With Active Psoriatic Arthritis (PHASE3)
- A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis (PHASE3)
- A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease (PHASE2, PHASE3)
- A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (PHASE3)
- A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2) (PHASE3)
- A Study of JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Matching Placebo to JNJ-77242113 CI brief — competitive landscape report
- Matching Placebo to JNJ-77242113 updates RSS · CI watch RSS
- Janssen Research & Development, LLC portfolio CI